Skip to content

A Real-World Cohort Study on the Efficacy of the Lung-Regulating and Asthma-Relieving Prescription in the Treatment of the Stable Phase of Chronic Obstructive Pulmonary Disease

A Real-World Cohort Study on the Efficacy of the Lung-Regulating and Asthma-Relieving Prescription in the Treatment of the Stable Phase of Chronic Obstructive Pulmonary Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000897
Enrollment
Unknown
Registered
2025-05-06
Start date
2025-05-06
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Exposure group:Prescription for Regulating the Lung and Relieving Asthma
Non-exposure group:Conventional basic treatment of Western medicine

Sponsors

Xuejia People's Hospital Xinbei District Changzhou City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnostic criteria for Chronic Obstructive Pulmonary Disease (COPD). 2. Patients aged between 40 and 85 years old. 3. Patients who have signed the informed consent form and have a high degree of compliance.

Exclusion criteria

Exclusion criteria: 1. Patients complicated with other diseases that can cause shortness of breath or dyspnea. 2. Patients who are currently participating in other drug clinical trials. 3. Pregnant women and women preparing for pregnancy as well as lactating women. 4. Patients who have had a concurrent infectious disease recently. 5. Patients complicated with severe primary diseases of the heart brain liver kidney hematopoietic endocrine system etc. those with liver and kidney insufficiency (ALT/AST/Cr greater than 1.5 times the upper limit of the normal value) and patients with mental illnesses.

Design outcomes

Primary

MeasureTime frame
The occurrence frequency of acute exacerbation of COPD within the trial cycle;Integral of Traditional Chinese Medicine symptoms;

Secondary

MeasureTime frame
Six-Minute Walk Test;The improvement of pulmonary function indicators;Modified Medical Research Council (mMRC) Dyspnea Scale Chronic Obstructive Pulmonary Disease;Assessment Test (CAT) Scale;

Countries

china

Contacts

Public ContactLIUJIAN

Xuejia People's Hospital Xinbei District Changzhou City

ss8738@163.com13616118792

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026